Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and/or asciminib
@article{ATM137645, author = {Yasushi Kubota}, title = {Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and/or asciminib}, journal = {Annals of Translational Medicine}, volume = {13}, number = {2}, year = {2025}, keywords = {}, abstract = {}, issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/137645} }